 "Lupin receives CDSCO's approval for anti-allergic drug bepotastine")
Lupin Limited has received approval for bepotastine tablets from the Central Drugs Standard Control Organisation (CDSCO) to market the product in India.
Bepotastine is a new second generation antihistamine medicine to be introduced into the Indian pharmaceutical market which could benefit millions of patients suffering from allergic symptoms. It is a rapid acting antihistamine that effectively controls day time and night time triggers of allergic symptoms. Bepotastine is approved by PMDA Japan and is actively marketed in Japan and other South East Asian countries.
The current market for plain antihistamines is estimated to be around Rs 860 crores growing at 14 percent, according to IMS MAT Mar 2017.
Naresh Gupta, president, Lupin Limited, said, “We have a rich legacy of addressing medical needs in the country and introducing treatments to combat them. I am sure that the approval of bepotastine would go a long way in addressing a common medical need for a safe and effective drug for the management of allergic symptoms.”
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%